Activating the immune system is not the challenge – a number of...

Activating the immune system is not the challenge – a number of technologies readily do that including radiotherapy and CAR-T therapy. The challenge lies in those activated immune cells being able to access the tumour cells and one of the key ways that cancer avoids the immune system is by blocking immune cells gaining entry to the tumour. This problem is identified as the main barrier to the universal success of immuno-oncology therapy. Veyonda may be the first drug known to overcome this problem, potentially turning so-called ‘COLD’ (immune-deficient) tumours into ‘HOT’ (immune-competent) tumours. That potential puts Veyonda in the front-line of cancer therapies and one of the most exciting drug prospects to emerge in recent years.

Disclosure:

Pitt Street Research receives fees from the company referred to in this document, for research services and other financial services or advice we may provide to that company... As part of due diligence, the analyst has independently and critically reviewed the assistance and information provided by the company to form the opinions expressed in the report. Diligent care has been taken by the analyst to maintain an honest and fair objectivity in writing this report and making the recommendation.